Article in Circulation. Heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
19 authors.
Mandana Chitsazan *Harvard Medical School, Boston, MA (M.C., L.B.K., J.L.J., J.E.H.).ORCID 0000-0003-4108-1620
Juhi K Parekh *CardioVascular Institute, Beth Israel Deaconess Medical Center, Boston, MA (M.C., J.K.P., L.B.K., S.M.N., J.E.H.).ORCID 0009-0009-6510-0073
Leah B KosyakovskyHarvard Medical School, Boston, MA (M.C., L.B.K., J.L.J., J.E.H.).ORCID 0000-0003-2482-0444
Sophie M NemethCardioVascular Institute, Beth Israel Deaconess Medical Center, Boston, MA (M.C., J.K.P., L.B.K., S.M.N., J.E.H.).ORCID 0009-0006-7988-775X
Emily S LauDivision of Cardiology, Massachusetts General Hospital, Boston (E.S.L., J.L.J.).ORCID 0000-0001-9361-6397
James L JanuzziHarvard Medical School, Boston, MA (M.C., L.B.K., J.L.J., J.E.H.).ORCID 0000-0002-8338-1798
Thomas J WangDepartment of Internal Medicine, UT Southwestern Medical Center, Dallas, TX (T.J.W.).ORCID 0000-0003-4063-6508
Chiadi E NdumeleDivision of Cardiology, Johns Hopkins University, Baltimore, MD (C.E.N.).ORCID 0000-0002-1603-282X
Elizabeth SelvinDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (E.S.).ORCID 0000-0001-6923-7151
Christie M BallantyneDepartment of Medicine, Baylor College of Medicine, Houston, TX (C.M.B.).ORCID 0000-0002-6432-1730
Bruce M PsatyCardiovascular Health Research Unit, Department of Medicine (B.M.P.), University of Washington, Seattle.ORCID 0000-0002-7278-2190
John S GottdienerDivision of Cardiology, University of Maryland School of Medicine, Baltimore, MD (J.S.G.).
Jorge R KizerCardiology Section, San Francisco VA Health Care System, CA (J.R.K.).ORCID 0000-0001-9936-7803
Christopher R deFilippiInova Schar Heart and Vascular, Falls Church, VA (C.R.F.).ORCID 0000-0002-0660-4943
Norrina B AllenDepartment of Preventive Medicine (N.B.A.), Northwestern University Feinberg School of Medicine, Chicago, IL.ORCID 0000-0002-6993-4384
Rudolf A de BoerErasmus MC, Cardiovascular Institute, Thorax Center, Department of Cardiology, Rotterdam, the Netherlands (R.A.d.B.).ORCID 0000-0002-4775-9140
Sanjiv J ShahDivision of Cardiology, Department of Medicine (S.J.S.), Northwestern University Feinberg School of Medicine, Chicago, IL.ORCID 0000-0002-5655-8201
Jennifer E HoHarvard Medical School, Boston, MA (M.C., L.B.K., J.L.J., J.E.H.).ORCID 0000-0002-7987-4768
Funding
Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Wake Forest Clinical and Translational Science AwardUL1TR001420 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ARD, JAMY D, FOLEY, KRISTIE L · 2015 to 2023
$32.3M
Clinical and Translational Science AwardUL1TR000040 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$26.2M
Task Area A Core Study Operations.Task Area A shall encompass annual follow-up of cohort members, clinical endpoints ascertainment, study coordination activities, maintenance of the database and biosp75N92020D00001 · NHLBI · UNIVERSITY OF WASHINGTON · PI MCCLELLAND, ROBYN LEAGH · 2020 to 2025
$17.2M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - COORDINATING CENTER - TASK AREA B.2 AND B.375N92022D00001 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COUPER, DAVID · 2022 to 2025
$13.7M
Exceptional Survival: Trajectories to Functional Aging (CHS All Stars)R01AG023629 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NEWMAN, ANNE B. · 2004 to 2016
$9.5M
CHARGE Consortium: Omics Discovery for CVD and Aging PhenotypesR01HL105756 · NHLBI · UNIVERSITY OF WASHINGTON · PI Bruce M Psaty, NICHOLAS L SMITH · 2011 to 2026
$9.5M
CARDIOVASCULAR HEALTH STUDY (CHS) - TASK AREA C, STUDY CLOSEOUT75N92021D00006 · NHLBI · UNIVERSITY OF WASHINGTON · PI PSATY, BRUCE · 2021 to 2024
$8.4M
CHS research resources for the cardiovascular health of older adultsU01HL130114 · NHLBI · UNIVERSITY OF WASHINGTON · PI BURKE, GREGORY L, KRONMAL, RICHARD A · 2016 to 2019
$6.6M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00003 · NHLBI · UNIVERSITY OF MINNESOTA · PI LUTSEY, PAMELA · 2022 to 2025
$5.1M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1M
THE ATHEROSCLEROSIS RISK IN COMMUNITIES (ARIC) STUDY - FIELD CENTER - TASK ORDER 01, TASK AREA A75N92022D00005 · NHLBI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI WAGENKNECHT, LYNNE E · 2022 to 2025
backgroundThe 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America guidelines introduced elevated natriuretic peptide (NP) levels as a criterion for defining stage B heart failure (HF), or pre-HF, to identify individuals at greatest risk for future HF. Given the known NP deficiency in obesity, we aimed to assess whether a single NP cut point would disproportionately up-classify individuals with versus without obesity to stage B HF.
methodsParticipants free of HF from 5 community-based cohorts were included. We examined the reclassification of individuals to stage B HF using the 2022 versus 2013 guidelines, stratified by obesity class. Cox proportional hazards models were used to assess the association of NPs with incident HF across obesity classes.
resultsAmong 32 735 participants, 35% had normal weight, 40% were overweight, 17% had obesity class 1, and 8% had obesity class 2/3. When applying the 2022 versus 2013 criteria, the proportion of individuals up-classified to stage B HF using the NP criterion was 62% among those with normal weight, 51% for those overweight, 47% for individuals with obesity class 1, and 42% for individuals with obesity class 2/3. Over a median follow-up of 13 years, 3077 HF events occurred. Both higher NP and body mass index were associated with greater HF risk, as expected (
conclusionsThe application of a single NP cut point resulted in fewer individuals with obesity being up-classified to stage B HF compared with normal-weight individuals. Adjusting NP cut points for individuals with obesity may improve the accuracy of HF risk stratification.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Natriuretic Peptide Cut Points for Heart Failure Classification in Individuals With and Without Obesity. · full record | OpenQuestion